FY25 Revenue Reaches $33.6M, Exceeding Expectations
Reports preliminary FY25 revenue $33.6M, consensus $33.5M. "We are pleased to report record results for the fourth quarter that exceeded our raised guidance issued in November," said Robert Spignesi, president and CEO. "For the full-year 2025, broad-based strength across systems, consumables and services delivered 20% revenue growth, including double-digit recurring revenue growth."
Trade with 70% Backtested Accuracy
Analyst Views on RPID
About RPID
About the author
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
Rapid Micro Biosystems (RPID) Reports Q4 Revenue of $11.3M, Raises 2025 Guidance to $33M
- Quarterly Revenue Growth: Rapid Micro Biosystems reported approximately $11.3 million in revenue for Q4, indicating sustained growth and strong market demand in the biosystems sector.
- Recurring Revenue Increase: The expected recurring revenue for Q4 2025 is approximately $4.6 million, representing a 10% growth compared to the prior-year period, reflecting steady improvements in customer base and product demand.
- Guidance Upgrade: Rapid Micro Biosystems raised its 2025 revenue guidance to at least $33 million, demonstrating the company's confidence in future performance and ongoing market demand.
- Surge in Multi-System Orders: The company secured a record number of multi-system orders during the reporting period, driving revenue growth and accelerating margin improvement, showcasing its competitiveness and enhanced market position.
Rapid Micro Biosystems (RPID) Projects 2025 Revenue of $33.6 Million, Up 20%
- Quarterly Revenue Expectation: Rapid Micro Biosystems anticipates preliminary unaudited fourth-quarter 2025 revenue of approximately $11.3 million, reflecting a robust 37% year-over-year growth that underscores the company's strong performance in the life sciences technology sector.
- Full-Year Revenue Outlook: The company projects full-year 2025 revenue to be around $33.6 million, representing a year-on-year growth of about 20%, indicating sustained demand for its products and increasing market recognition.
- Recurring Revenue Growth: Expected recurring revenue for the fourth quarter is $4.6 million, while full-year recurring revenue is forecasted at $17.8 million, showcasing the company's solid performance in establishing stable revenue streams.
- Future Guidance: Rapid Micro Biosystems plans to release full audited results and its 2026 outlook in the first quarter, further enhancing investor confidence in the company's future growth trajectory.
Highlights from Rapid Micro Biosystems Inc (RPID) Q3 2025 Earnings Call: Record Revenue Achieved
Third Quarter Financial Performance: Rapid Micro Biosystems Inc reported Q3 revenue of $7.8 million, with consumables revenue up 40% and service revenue increasing by 12%, contributing to a 30% year-over-year rise in recurring revenue.
Record Multi-System Order: The company secured a significant multi-system order from a top biopharma customer, indicating strong commercial momentum, although they anticipate a temporary decrease in service revenue in Q4.
Collaboration and Margin Outlook: Progress with Millipore Sigma is expected to enhance margins starting in the second half of 2026, despite current product margins being slightly negative.
Future Expectations: The company expects onshoring to positively impact business in 2027 and beyond, while gross margins for Q4 are projected to be in the mid-single digits due to ongoing profitability challenges.
RAPID MICRO BIOSYSTEMS, INC. Reports Q3 Loss Below Expectations
Third Quarter Loss: RAPID MICRO BIOSYSTEMS, INC. reported a loss of -$11.51 million for the third quarter, which was worse than analysts' expectations of -$0.25 per share.
Revenue Growth: The company's revenue increased by 3.2% to $7.84 million compared to $7.60 million in the same period last year.
Earnings Comparison: The earnings per share remained unchanged at -$0.26, consistent with the previous year.
Full Year Guidance: The company provided a full-year revenue guidance of $33.0 million.
Rapid Micro Biosystems to Attend the Stifel 2025 Healthcare Conference
Company Participation: Rapid Micro Biosystems will participate in the Stifel 2025 Healthcare Conference on November 11, 2025, with a 30-minute Q&A session available via live webcast.
Company Overview: Rapid Micro Biosystems specializes in automation solutions for the healthcare sector, enhancing the manufacturing and quality control processes for products like biologics and vaccines through their Growth Direct system.
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
Rapid Micro Biosystems (RPID) Reports Q4 Revenue of $11.3M, Raises 2025 Guidance to $33M
- Quarterly Revenue Growth: Rapid Micro Biosystems reported approximately $11.3 million in revenue for Q4, indicating sustained growth and strong market demand in the biosystems sector.
- Recurring Revenue Increase: The expected recurring revenue for Q4 2025 is approximately $4.6 million, representing a 10% growth compared to the prior-year period, reflecting steady improvements in customer base and product demand.
- Guidance Upgrade: Rapid Micro Biosystems raised its 2025 revenue guidance to at least $33 million, demonstrating the company's confidence in future performance and ongoing market demand.
- Surge in Multi-System Orders: The company secured a record number of multi-system orders during the reporting period, driving revenue growth and accelerating margin improvement, showcasing its competitiveness and enhanced market position.
Rapid Micro Biosystems (RPID) Projects 2025 Revenue of $33.6 Million, Up 20%
- Quarterly Revenue Expectation: Rapid Micro Biosystems anticipates preliminary unaudited fourth-quarter 2025 revenue of approximately $11.3 million, reflecting a robust 37% year-over-year growth that underscores the company's strong performance in the life sciences technology sector.
- Full-Year Revenue Outlook: The company projects full-year 2025 revenue to be around $33.6 million, representing a year-on-year growth of about 20%, indicating sustained demand for its products and increasing market recognition.
- Recurring Revenue Growth: Expected recurring revenue for the fourth quarter is $4.6 million, while full-year recurring revenue is forecasted at $17.8 million, showcasing the company's solid performance in establishing stable revenue streams.
- Future Guidance: Rapid Micro Biosystems plans to release full audited results and its 2026 outlook in the first quarter, further enhancing investor confidence in the company's future growth trajectory.
Highlights from Rapid Micro Biosystems Inc (RPID) Q3 2025 Earnings Call: Record Revenue Achieved
Third Quarter Financial Performance: Rapid Micro Biosystems Inc reported Q3 revenue of $7.8 million, with consumables revenue up 40% and service revenue increasing by 12%, contributing to a 30% year-over-year rise in recurring revenue.
Record Multi-System Order: The company secured a significant multi-system order from a top biopharma customer, indicating strong commercial momentum, although they anticipate a temporary decrease in service revenue in Q4.
Collaboration and Margin Outlook: Progress with Millipore Sigma is expected to enhance margins starting in the second half of 2026, despite current product margins being slightly negative.
Future Expectations: The company expects onshoring to positively impact business in 2027 and beyond, while gross margins for Q4 are projected to be in the mid-single digits due to ongoing profitability challenges.
RAPID MICRO BIOSYSTEMS, INC. Reports Q3 Loss Below Expectations
Third Quarter Loss: RAPID MICRO BIOSYSTEMS, INC. reported a loss of -$11.51 million for the third quarter, which was worse than analysts' expectations of -$0.25 per share.
Revenue Growth: The company's revenue increased by 3.2% to $7.84 million compared to $7.60 million in the same period last year.
Earnings Comparison: The earnings per share remained unchanged at -$0.26, consistent with the previous year.
Full Year Guidance: The company provided a full-year revenue guidance of $33.0 million.
Rapid Micro Biosystems to Attend the Stifel 2025 Healthcare Conference
Company Participation: Rapid Micro Biosystems will participate in the Stifel 2025 Healthcare Conference on November 11, 2025, with a 30-minute Q&A session available via live webcast.
Company Overview: Rapid Micro Biosystems specializes in automation solutions for the healthcare sector, enhancing the manufacturing and quality control processes for products like biologics and vaccines through their Growth Direct system.
